Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medifast (MED) Current Deferred Revenue (2018 - 2020)

Medifast's Current Deferred Revenue history spans 3 years, with the latest figure at $7.6 million for Q4 2020.

  • For Q4 2020, Current Deferred Revenue rose 75.54% year-over-year to $7.6 million; the TTM value through Dec 2020 reached $7.6 million, up 75.54%, while the annual FY2020 figure was $7.6 million, 75.54% up from the prior year.
  • Current Deferred Revenue reached $7.6 million in Q4 2020 per MED's latest filing, up from $4.3 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $7.6 million in Q4 2020 to a low of $2.8 million in Q4 2018.
  • Average Current Deferred Revenue over 3 years is $4.9 million, with a median of $4.3 million recorded in 2019.
  • Peak YoY movement for Current Deferred Revenue: soared 54.92% in 2019, then soared 75.54% in 2020.
  • A 3-year view of Current Deferred Revenue shows it stood at $2.8 million in 2018, then skyrocketed by 54.92% to $4.3 million in 2019, then skyrocketed by 75.54% to $7.6 million in 2020.
  • Per Business Quant, the three most recent readings for MED's Current Deferred Revenue are $7.6 million (Q4 2020), $4.3 million (Q4 2019), and $2.8 million (Q4 2018).